Neuropathic Pain Clinical Trial
Official title:
Brain Activation During Thermal Stimulation in Neuropathic Pain
Patients with peripheral neuropathy frequently exhibit treatment-refractory neuropathic pain. Although both peripheral and central determinants are recognized for the pathophysiological basis of neuropathic pain following peripheral injury, the modulating effect on pain processing in brain by peripheral mechanisms remains elusive. Here, we will systematically compare the sensory symptoms and brain activation to painful heat stimulation applied to the foot dorsum between patients with peripheral neuropathy and healthy controls. Functional magnetic resonance imaging will be used to define brain activation to thermal stimulation with noxious heat and innocuous warm thermal stimuli applied by contact heat stimulator. Brain activation during thermal stimulation in patients with neuropathic pain will be clarified, and we will also analyze the potential relationships between the topography, quality and intensity of the different painful symptoms and the magnitude and pattern of brain activation during thermal stimulation. This will add in our understanding in the pathophysiology of brain modulation in pain and provide clinically useful message toward the potential therapeutics in the management of neuropathic pain.
Patients with peripheral neuropathy and healthy volunteers will be recruited in this study.
Peripheral neuropathy is defined according to the neuropathic symptoms and signs. Informed
consent will be approved by the Ethical Committee of the National Taiwan University Hospital
and obtained from each subject.
To assess the severity of different neuropathic symptoms, such as spontaneous ongoing and
paroxysmal pain, evoked pain, paraesthesia, and dysaesthesia, patients with neuropathic pain
will fill out the Neuropathic Pain Symptom Inventory. Each subject will receive detailed
sensory examination to evaluate the integrity of sensory fibers. To measure thresholds of
thermal and vibratory sensations, we will perform quantitative sensory testing by the method
of level using a Thermal Sensory Analyser and Vibratory Sensory Analyser (Medoc Advanced
Medical System, Minneapolis, MN, USA) following an established protocol. We will use a
contact heat stimulator to deliver thermal stimulation. Noxious and innocuous heat
temperatures will be applied within the right foot dorsum. Several pretests will be applied
before CHEP recording to eliminate expectation effects. To avoid sensitization and
desensitization, low intensity stimuli will precede high intensity stimuli at each block.
Functional magnetic resonance imaging (fMRI) will be performed on a 3-T MR machine (Sonata;
Siemens, Erlangen, Germany). A high resolution T1 weighted scan of the entire brain in
trans-axial orientation will be obtained to provide anatomical information for the
superimposed functional activation maps. Echo Planar Imaging will be used for the
acquisition of the functional data. Each imaging session will be consisted of one
high-resolution anatomical scan and three functional scanning runs, with 5-min intersession
interval. During the scanning, several thermal stimuli will be applied by CHEP stimulator to
the right dorsal foot. To avoid sensitization, the stimulation site will be changed slightly
after each stimulus. After 12-s stimulation, the temperature will be cooling, with a
subsequent 36-s interstimulus interval. After each fMRI session, subjects will be asked to
rate the intensity and unpleasantness of received pain stimulus. The average rating values
will be indicated after the scan on a computer driven visual analogue scale ranging from 0
to 10 (0, no pain; 1, slight intense; 2, mild intense; 3, moderate intense; 4, slight pain;
5, mild pain; 6, moderate pain; 7, moderate-strong pain; 8, strong pain; 9, severe pain; 10,
unbearable pain), and the intensity and unpleasantness of received pain will be assessed
using the Short-Form McGill Pain Questionnaire.
All data will be processed using the Statistical Parametric Mapping software (SPM2). fMRI
data series will be realigned and resliced with sinc interpolation to correct for motion
artifacts. Scans with sudden head movements of more than 2 mm will be omitted. To enable
intersubject analysis, the functional data will be coregistered to the anatomical scan and
transformed into a reference space according to the MNI template of SPM2 by normalization
using sinc interpolation. The resampled voxel volume of the normalized images is 2 x 2 x 2
mm. Subsequently, data will be smoothed with an isotropic Gaussian kernel of 8 mm full-width
at half maximum to reduce high frequency noise and to account for anatomical variances.
Condition-specific effects will be estimated with the general linear model using a boxcar
approach convolved with the hemodynamic response function. High pass filtering will remove
low frequency noise and low pass filtering will account for serial autocorrelations of the
data.
We will analyze the data on an individual (subject per subject) basis and across subjects
(group analysis) using a cross-subjects variance (random effect analysis). Data from each
stimulation will be pooled for group statistical comparisons. A single design matrix,
including 3 sessions of all subjects, will be generated due to the limited number of
experiments representing a fixed-effects model analysis. Statistical parametric maps will be
generated as t-contrasts and corrected for multiple comparisons according to the random
field theory with P < 0.05. The threshold for the Z maps is 3.09 (P < 0.001) for individual
subject analysis. Significant clusters have to show a minimum extension volume of 10 voxels.
;
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04699734 -
Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Completed |
NCT05235191 -
Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies
|
Phase 3 | |
Completed |
NCT05845177 -
Persistent Pain After Hip Replacement
|
||
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05949554 -
Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
|
||
Withdrawn |
NCT05052645 -
Ear Acupuncture for Neuropathic Pain
|
N/A | |
Completed |
NCT02930551 -
Neuromas as the Cause of Pain
|
N/A | |
Completed |
NCT02866396 -
Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
|
||
Completed |
NCT02824588 -
Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain
|
N/A | |
Active, not recruiting |
NCT02560545 -
Cannabinoids Effects on the Pain Modulation System
|
N/A | |
Enrolling by invitation |
NCT02485795 -
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management
|
N/A | |
Completed |
NCT02099890 -
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury
|
Phase 3 | |
Not yet recruiting |
NCT02246517 -
The Effect of N2O on Chronic Neuropathic Pain Patients
|
Phase 0 | |
Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
Completed |
NCT01884662 -
Virtual Walking for Neuropathic Pain in Spinal Cord Injury
|
N/A | |
Completed |
NCT01718821 -
Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients
|
N/A | |
Completed |
NCT01669967 -
The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin
|
N/A | |
Completed |
NCT01207596 -
Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain
|
Phase 4 | |
Completed |
NCT01201317 -
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
|
Phase 2 |